Give and Takeda

23 Apr 2018 By Jeffrey Goldfarb

The Japanese drugmaker led by a French CEO added cash to a slightly sweeter $60 bln bid for Irish rival Shire. Takeda’s target is cheap, but the big premium will be hard to justify. The deal also would flood the market with shares and ratchet up debt. It’s all a big stretch.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)